Next Article in Journal
Decoding the Role of CD271 in Melanoma
Next Article in Special Issue
The Role of PPARγ Ligands in Breast Cancer: From Basic Research to Clinical Studies
Previous Article in Journal
Sonographic Risk Stratification Systems for Thyroid Nodules as Rule-Out Tests in Older Adults
 
 
Review

STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy

by 1,2, 1,3, 1,3,* and 1,2,*
1
The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041, Guangdong, China
2
Institute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, Guangdong, China
3
Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou 515041, Guangdong, China
*
Authors to whom correspondence should be addressed.
Cancers 2020, 12(9), 2459; https://doi.org/10.3390/cancers12092459
Received: 26 July 2020 / Revised: 25 August 2020 / Accepted: 27 August 2020 / Published: 30 August 2020
(This article belongs to the Special Issue Tumor Suppressor Genes: Insight into the Cancer Therapy)
STAT3, an oncogene, contributes to insensitivity of chemotherapy and radiotherapy in tumor, reduces the clinical efficacy. Meanwhile, STAT3β, a STAT3 splicing isoform, is related to the inhibition of tumor growth and chemosensitivity. STAT3 may become a potential target to overcome the chemo(radio)resistance, which benefit for developing novel drugs targeting STAT3 or alternative splicing regulators.
Chemoradiotherapy is one of the most effective and extensively used strategies for cancer treatment. Signal transducer and activator of transcription 3 (STAT3) regulates vital biological processes, such as cell proliferation and cell growth. It is constitutively activated in various cancers and limits the application of chemoradiotherapy. Accumulating evidence suggests that STAT3 regulates resistance to chemotherapy and radiotherapy and thereby impairs therapeutic efficacy by mediating its feedback loop and several target genes. The alternative splicing product STAT3β is often identified as a dominant-negative regulator, but it enhances sensitivity to chemotherapy and offers a new and challenging approach to reverse therapeutic resistance. We focus here on exploring the role of STAT3 in resistance to receptor tyrosine kinase (RTK) inhibitors and radiotherapy, outlining the potential of targeting STAT3 to overcome chemo(radio)resistance for improving clinical outcomes, and evaluating the importance of STAT3β as a potential therapeutic approach to overcomes chemo(radio)resistance. In this review, we discuss some new insights into the effect of STAT3 and its subtype STAT3β on chemoradiotherapy sensitivity, and we explore how these insights influence clinical treatment and drug development for cancer. View Full-Text
Keywords: chemoresistance; radioresistance; STAT3; STAT3β; target therapy chemoresistance; radioresistance; STAT3; STAT3β; target therapy
Show Figures

Figure 1

MDPI and ACS Style

Yang, P.-L.; Liu, L.-X.; Li, E.-M.; Xu, L.-Y. STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy. Cancers 2020, 12, 2459. https://doi.org/10.3390/cancers12092459

AMA Style

Yang P-L, Liu L-X, Li E-M, Xu L-Y. STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy. Cancers. 2020; 12(9):2459. https://doi.org/10.3390/cancers12092459

Chicago/Turabian Style

Yang, Ping-Lian, Lu-Xin Liu, En-Min Li, and Li-Yan Xu. 2020. "STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy" Cancers 12, no. 9: 2459. https://doi.org/10.3390/cancers12092459

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop